Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.

摘要: BACKGROUND The overexpression of HER-2 occurs in a minority patients with nonsmall cell lung carcinoma. Trastuzumab, which is monoclonal antibody to HER-2, an effective treatment some women breast carcinomas that overexpress as demonstrated by immunohistochemistry. The objective this Phase II study was determine whether trastuzumab would effect responses carcinoma who had tumors overexpressed HER-2. METHODS Patients were required have Stage IIIB or IV and 2+ 3+ expression determined immunohistochemistry, they may received up 1 prior chemotherapy regimen. Trastuzumab at dose 4 mg/kg given intravenously on Week 1; then, weekly doses 2 given. Response revaluation performed every 8 weeks. RESULTS Among 209 screened patients, 24 (11%) HER-2. One patient achieved partial response, one experienced treatment-related death due pulmonary toxicity. CONCLUSIONS Single-agent did not exhibit significant clinical activity against when levels measured Cancer 2005. © 2005 American Society.